Claret Medical, a Santa Rosa, CA-based developer of products for cerebral protection during structural heart, vascular and cardiac surgery procedures, raised $18m Series B funding.
The round was led by Santé Ventures with participation from Lightstone Ventures and Easton Capital. In conjunction with the funding, James Eadie from Santé Ventures and Hank Plain from Lightstone Ventures will join Claret Medical’s board of directors.
The company intends to use the funds to complete the U.S. pivotal trial of its Sentinel™ Cerebral Protection System (CPS) for embolic protection during transcatheter aortic valve replacement (TAVR), which received Investigational Device Exemption (IDE) approval earlier this year.
Led by Azin Parhizgar, PhD, President and Chief Executive Officer, Claret Medical develops solutions for cerebral protection during structural heart, vascular and cardiac surgery procedures. The company is currently focusing product development and clinical research on addressing the problem of stroke during TAVR. Its The Sentinel CPS is a filter-based system that both captures and removes embolic debris released during TAVR procedures that could otherwise be a source of peri-procedural stroke.
It has been used in more than 800 procedures worldwide to date.